Fig. 3
Bootstrap Distribution of Cost-Effectiveness: Comparative Analysis between Risankizumab and Adalimumab Incorporating Real Utilization Rates and Costs
Fig. 3 | Cost Effectiveness and Resource Allocation
Bootstrap Distribution of Cost-Effectiveness: Comparative Analysis between Risankizumab and Adalimumab Incorporating Real Utilization Rates and Costs